沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果观察

Therapeutic Effect of Thalidomide Combined with Gefitinib on Non-small Cell Lung Cancer

目的:探讨沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果。方法:选取2014年1月-2016年12月我院收治的非小细胞肺癌患者79例,按照治疗方法的不同分为对照组40例、观察组39例。对照组进行常规非小细胞肺癌治疗,观察组在手术前给予沙利度胺联合吉非替尼靶向治疗后行常规治疗。比较两组临床疗效,6个月、1年生存率,并记录观察组患者不良反应的发生情况。结果:观察组化疗的化疗缓解率(71.79%)显著高于对照组(52.50%)(P<0.05)。观察组患者在治疗期间出现了不同程度的白细胞减少、、恶心呕吐、关节痛、脱发、肝功能损伤等不良反应,患者对以上症状均可耐受,给予对症治疗后均自行缓解。观察组患者6个月、1年生存率均显著高于对照组(P<0.05)。结论:沙利度胺联合吉非替尼靶向治疗NSCLC患者的疗效较好,能显著提高患者生存率。

Objective: To explore the clinical efficacy of thalidomide combined with gefitinib in the treatment of non-small cell lung cancer. Methods: Selected 79 NSCLC patients admitted to our hospital from January 2014 to December 2016. All patients were divided into control group(n=40) and observation group(n=39) by treatment methods. The control group received NSCLC routine treatment. The observation group was given thalidomide combined with gefitinib targeted therapy before surgery, then received routine treatment. The clinical efficacy, 6 months and 1 year survival rates between two groups were compared. The incidence of adverse reactions in the observation group was recorded. Results: The chemotherapy remission rate in the observation group(71.79 %) was significantly higher than that in the control group(52.50 %)(P<0.05). The patients in the observation group experienced various adverse reactions such as neutropenia, nausea and vomiting, joint pain, hair loss, and liver function impairment during the treatment period. Patients can tolerate the above symptoms, and they all relieve themselves after symptomatic treatment. The 6-month and 1-year survival rates in the observation group were significantly higher than those in the control group(P<0.05). Conclusions: Thalidomide combined with gefitinib is effective in the treatment of NSCLC patients and can significantly improve the survival rate of patients. It is worth further study.